GJD3

Summary

GJD3 (gap junction protein delta 3, HGNC:19147) is a protein-coding gene on chromosome 17q21.2, encoding Gap junction delta-3 protein (Q8N144). One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.

This gene is a member of the large family of connexins that are required for the formation of gap junctions. Six connexin monomers form a hemichannel, or connexon, on the cell surface. This connexon can interact with a connexon from a neighboring cell, thus forming a channel linking the cytoplasm of the 2 cells.

Source: NCBI Gene 125111 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 57 total
• MANE Select transcript: NM_152219

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19147
Approved symbol	GJD3
Name	gap junction protein delta 3
Location	17q21.2
Locus type	gene with protein product
Status	Approved
Aliases	CX31.9, GJA11, Cx30.2
Ensembl gene	ENSG00000183153
Ensembl biotype	protein_coding
OMIM	607425
Entrez	125111

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000578689

RefSeq mRNA: 1 — MANE Select: NM_152219 NM_152219

CCDS: CCDS58547

Canonical transcript exons

ENST00000578689 — 1 exons

Exon	Start	End
ENSE00002729383	40360652	40364737

Expression profiles

Bgee: expression breadth ubiquitous, 157 present calls, max score 82.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.5710 / max 74.8246, expressed in 1130 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
166400	3.5710	1130
166401	1.4925	542
166402	0.7304	467
166398	0.4082	233
166399	0.1660	77
165709	0.1605	92

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.10	gold quality
apex of heart	UBERON:0002098	81.78	gold quality
pancreatic ductal cell	CL:0002079	77.91	silver quality
left ventricle myocardium	UBERON:0006566	77.38	gold quality
cardiac muscle of right atrium	UBERON:0003379	76.65	gold quality
spleen	UBERON:0002106	73.84	gold quality
ileal mucosa	UBERON:0000331	71.93	gold quality
upper arm skin	UBERON:0004263	71.53	gold quality
epithelial cell of pancreas	CL:0000083	71.35	gold quality
stromal cell of endometrium	CL:0002255	70.91	gold quality
myocardium	UBERON:0002349	70.89	gold quality
heart left ventricle	UBERON:0002084	69.27	gold quality
cardiac ventricle	UBERON:0002082	69.13	gold quality
right lung	UBERON:0002167	69.08	gold quality
gall bladder	UBERON:0002110	68.90	gold quality
mucosa of transverse colon	UBERON:0004991	68.72	gold quality
smooth muscle tissue	UBERON:0001135	68.34	gold quality
upper lobe of left lung	UBERON:0008952	68.22	gold quality
vermiform appendix	UBERON:0001154	67.95	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	67.86	gold quality
right lobe of thyroid gland	UBERON:0001119	67.83	gold quality
upper lobe of lung	UBERON:0008948	67.49	gold quality
metanephros cortex	UBERON:0010533	67.35	gold quality
left lobe of thyroid gland	UBERON:0001120	67.10	gold quality
prostate gland	UBERON:0002367	67.08	gold quality
metanephros	UBERON:0000081	66.31	gold quality
thyroid gland	UBERON:0002046	66.16	gold quality
caecum	UBERON:0001153	65.87	gold quality
tibialis anterior	UBERON:0001385	65.86	silver quality
seminal vesicle	UBERON:0000998	65.82	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

52 targeting GJD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-3151-5P	99.86	63.83	1069
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-4756-3P	99.62	66.30	1319
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-549A-3P	99.54	68.17	825
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-8064	99.45	66.92	875
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3911	99.38	66.95	1087

Literature-anchored findings (GeneRIF, showing 8)

• Results describe the identification of a novel human gap junction gene that encodes a protein designated HCx31.9 (connexin 31.9). (PMID:12064584)
• Connexin 31.9 represents a novel connexin gene that in vivo generates a protein with unique voltage gating properties. (PMID:12154091)
• expression patterns differ from mouse orthologs [Cx30.2; Cx40.1] (PMID:12881038)
• Hemichannels formed of mCx30.2 and hCx31.9 may slow propagation of excitation in the sinoatrial and atrioventricular nodes by shortening the space constant and depolarizing the excitable membrane (PMID:16772377)
• Exogenous Cx31 expression induced neurite outgrowth in human neuronal cell lines, but not differentiation in primary human keratinocytes. (PMID:17142249)
• Our data suggest that connexin30.2 can form heteromers with the other cardiac connexins. (PMID:18291099)
• Cx31.9 protein, unlike its counterpart in the mouse, is not expressed in detectable quantities and is thus unlikely to contribute to the impulse generation and conduction system or the working myocardium of the human heart. (PMID:19168070)
• Connexin expression decreases during adipogenic differentiation of human adipose-derived mesenchymal stem cells. (PMID:33141287)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gjd3	ENSMUSG00000047197
rattus_norvegicus	Gjd3	ENSRNOG00000051691

Paralogs (20): GJA8 (ENSG00000121634), GJB6 (ENSG00000121742), GJA3 (ENSG00000121743), GJA9 (ENSG00000131233), GJA10 (ENSG00000135355), GJA1 (ENSG00000152661), GJD2 (ENSG00000159248), GJB7 (ENSG00000164411), GJB2 (ENSG00000165474), GJB1 (ENSG00000169562), GJC3 (ENSG00000176402), GJD4 (ENSG00000177291), GJC1 (ENSG00000182963), GJA4 (ENSG00000187513), GJB3 (ENSG00000188910), GJB5 (ENSG00000189280), GJB4 (ENSG00000189433), GJC2 (ENSG00000198835), GJE1 (ENSG00000203733), GJA5 (ENSG00000265107)

Protein

Protein identifiers

Gap junction delta-3 protein — Q8N144 (reviewed: Q8N144)

Alternative names: Connexin-31.9, Gap junction alpha-11 protein, Gap junction chi-1 protein

All UniProt accessions (2): A0A654IC68, Q8N144

UniProt curated annotations — full annotation on UniProt →

Function. One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell.

Subunit / interactions. A connexon is composed of a hexamer of connexins. Interacts with TJP1.

Subcellular location. Cell membrane. Cell junction. Gap junction.

Tissue specificity. Expressed in vascular smooth muscle cells. Found in heart, colon, and artery (at protein level). Found in cerebral cortex, heart, liver, lung, kidney, spleen and testis.

Similarity. Belongs to the connexin family. Delta-type subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8N144-1	1	yes
Q8N144-2	2

RefSeq proteins (1): NP_689343* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000500	Connexin	Family
IPR013092	Connexin_N	Domain
IPR017990	Connexin_CS	Conserved_site
IPR019570	Connexin_CCC	Domain
IPR038359	Connexin_N_sf	Homologous_superfamily

Pfam: PF00029

UniProt features (13 total): topological domain 5, transmembrane region 4, chain 1, region of interest 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N144-F1	78.25	0.45

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-190861	Gap junction assembly

MSigDB gene sets: 256 (showing top): GOBP_MUSCLE_TISSUE_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOCC_CELL_SURFACE, REACTOME_MEMBRANE_TRAFFICKING, GOBP_CELL_CELL_SIGNALING, BROWNE_HCMV_INFECTION_48HR_DN, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, IRF7_01, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_NEGATIVE_REGULATION_OF_BLOOD_CIRCULATION, GOBP_MUSCLE_CONTRACTION, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2, GOBP_CELL_COMMUNICATION_INVOLVED_IN_CARDIAC_CONDUCTION

GO Biological Process (10): cell communication (GO:0007154), cell-cell signaling (GO:0007267), response to glucose (GO:0009749), negative regulation of heart rate (GO:0010459), gap junction assembly (GO:0016264), negative regulation of cardiac conduction (GO:1903780), monoatomic ion transmembrane transport (GO:0034220), transmembrane transport (GO:0055085), AV node cell to bundle of His cell communication by electrical coupling (GO:0086053), negative regulation of cell communication by electrical coupling involved in cardiac conduction (GO:1901845)

GO Molecular Function (4): monoatomic ion channel activity (GO:0005216), gap junction channel activity involved in AV node cell-bundle of His cell electrical coupling (GO:0086077), gap junction channel activity (GO:0005243), protein binding (GO:0005515)

GO Cellular Component (6): plasma membrane (GO:0005886), connexin complex (GO:0005922), cell surface (GO:0009986), gap junction (GO:0005921), membrane (GO:0016020), anchoring junction (GO:0070161)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gap junction trafficking	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
cell communication by electrical coupling involved in cardiac conduction	2
cellular anatomical structure	2
cell communication	1
signaling	1
response to hexose	1
regulation of heart rate	1
negative regulation of heart contraction	1
cell-cell junction assembly	1
negative regulation of biological process	1
cardiac conduction	1
regulation of cardiac conduction	1
monoatomic ion transport	1
transmembrane transport	1
transport	1
AV node cell to bundle of His cell communication	1
negative regulation of cell communication by electrical coupling	1
regulation of cell communication by electrical coupling involved in cardiac conduction	1
monoatomic ion transmembrane transporter activity	1
channel activity	1
AV node cell to bundle of His cell communication by electrical coupling	1
gap junction channel activity involved in cardiac conduction electrical coupling	1
wide pore channel activity	1
binding	1
membrane	1
cell periphery	1
gap junction	1
plasma membrane protein complex	1
cell-cell junction	1
cell junction	1

Protein interactions and networks

STRING

392 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GJD3	TJP1	Q07157	861
GJD3	GJE1	A6NN92	554
GJD3	GJC1	P36383	509
GJD3	HCN4	Q9Y3Q4	452
GJD3	TBX3	O15119	428
GJD3	TBX5	Q99593	370
GJD3	CACNA1G	O43497	348
GJD3	ZNF324	O75467	335
GJD3	TBX2	Q13207	331
GJD3	ZNF324B	Q6AW86	329
GJD3	SCN5A	Q14524	327
GJD3	TBX18	O95935	318
GJD3	SHOX2	O60902	315
GJD3	PRKAB2	O43741	303
GJD3	CHD1L	Q86WJ1	298

IntAct

5 interactions, top by confidence:

A	B	Type	Score
GJD3	TJP1	psi-mi:“MI:0915”(physical association)	0.520
BMP2K	GJD3	psi-mi:“MI:0915”(physical association)	0.490

BioGRID (453): AAAS (Proximity Label-MS), ABCC1 (Proximity Label-MS), ACBD3 (Proximity Label-MS), ACSL3 (Proximity Label-MS), ADCY9 (Proximity Label-MS), ADD3 (Proximity Label-MS), LPHN2 (Proximity Label-MS), ALCAM (Proximity Label-MS), ALDH3A2 (Proximity Label-MS), ANKLE2 (Proximity Label-MS), ANKRD26 (Proximity Label-MS), ANO6 (Proximity Label-MS), APBB1 (Proximity Label-MS), APBB2 (Proximity Label-MS), APOL2 (Proximity Label-MS)

ESM2 similar proteins: A3KN95, A4IFG4, A7E2I7, E2RDP2, J3QMI4, O94810, O95382, P0C5W1, P23677, P82350, Q15628, Q16586, Q1RMX3, Q24JP5, Q28686, Q29RH2, Q3T904, Q3U0S6, Q45T69, Q49LS1, Q5FWU3, Q5RCS0, Q5U651, Q64255, Q674R7, Q684M2, Q68FE2, Q68FE7, Q6EBV9, Q6GQT5, Q6NY19, Q6P9Q4, Q6PEY1, Q7Z3C6, Q80WF4, Q80XF7, Q86TL0, Q86XJ0, Q8C052, Q8C152

Diamond homologs: A2VE67, A3KN25, A4GG66, A4GVD1, A4IFL1, A6XKM2, O18968, O57474, O93533, O95377, O95452, P08033, P08034, P08050, P08983, P14154, P16863, P16864, P17302, P18246, P18860, P18861, P21994, P23242, P25305, P28228, P28229, P28230, P28231, P28232, P28233, P28234, P28235, P28236, P29033, P29414, P29415, P33725, P35212, P36381

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

57 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

924 predictions. Top by Δscore:

Variant	Effect	Δscore
17:44804036:T:TA	donor_gain	1.0000
17:44805834:TGCC:T	acceptor_gain	1.0000
17:44805836:CC:C	acceptor_gain	1.0000
17:44805836:CCCT:C	acceptor_loss	1.0000
17:44805837:CCTGA:C	acceptor_gain	1.0000
17:44805838:C:CG	acceptor_loss	1.0000
17:44805839:T:A	acceptor_loss	1.0000
17:44805847:G:C	acceptor_gain	1.0000
17:44805847:G:GC	acceptor_gain	1.0000
17:44807389:TTTA:T	donor_loss	1.0000
17:44807390:TTA:T	donor_loss	1.0000
17:44807391:TA:T	donor_loss	1.0000
17:44807392:A:C	donor_loss	1.0000
17:44807393:C:A	donor_loss	1.0000
17:44807465:TCCCT:T	acceptor_gain	1.0000
17:44807466:CCCT:C	acceptor_gain	1.0000
17:44807466:CCCTC:C	acceptor_gain	1.0000
17:44807467:CCTC:C	acceptor_gain	1.0000
17:44807468:CT:C	acceptor_gain	1.0000
17:44807470:C:CA	acceptor_loss	1.0000
17:44807470:C:CC	acceptor_gain	1.0000
17:44804032:AACCT:A	donor_gain	0.9900
17:44805833:ATGCC:A	acceptor_gain	0.9900
17:44805835:GCC:G	acceptor_gain	0.9900
17:44805836:CCC:C	acceptor_gain	0.9900
17:44805838:C:CC	acceptor_gain	0.9900
17:44805838:C:T	acceptor_gain	0.9900
17:44805841:A:C	acceptor_gain	0.9900
17:44805859:C:CT	acceptor_gain	0.9900
17:44807467:CCT:C	acceptor_gain	0.9900

AlphaMissense

1847 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:40363661:A:C	F52C	0.999
17:40363682:A:C	F45C	0.999
17:40363660:G:C	F52L	0.998
17:40363660:G:T	F52L	0.998
17:40363662:A:G	F52L	0.998
17:40363681:G:C	F45L	0.998
17:40363681:G:T	F45L	0.998
17:40363683:A:G	F45L	0.998
17:40363279:G:C	C179W	0.997
17:40363606:G:C	F70L	0.997
17:40363606:G:T	F70L	0.997
17:40363608:A:G	F70L	0.997
17:40363651:G:C	N55K	0.997
17:40363651:G:T	N55K	0.997
17:40363655:C:G	C54S	0.997
17:40363655:C:T	C54Y	0.997
17:40363656:A:T	C54S	0.997
17:40363661:A:G	F52S	0.997
17:40363255:C:A	K187N	0.996
17:40363255:C:G	K187N	0.996
17:40363258:C:A	E186D	0.996
17:40363258:C:G	E186D	0.996
17:40363276:G:C	F180L	0.996
17:40363276:G:T	F180L	0.996
17:40363277:A:C	F180C	0.996
17:40363278:A:G	F180L	0.996
17:40363280:C:G	C179S	0.996
17:40363280:C:T	C179Y	0.996
17:40363281:A:T	C179S	0.996
17:40363607:A:C	F70C	0.996

dbSNP variants (sampled 300 via entrez): RS1000108930 (17:40363960 G>A), RS1000177893 (17:40362693 G>A), RS1000923898 (17:40360768 A>G), RS1002055758 (17:40365004 T>G), RS1002111781 (17:40366669 A>C,G,T), RS1002181329 (17:40365699 G>A), RS1002241443 (17:40360636 A>G), RS1002571863 (17:40362166 GCACA>G,GCA), RS1002924704 (17:40364695 C>T), RS1003965174 (17:40366628 G>A), RS1004122980 (17:40364920 C>T), RS1004521322 (17:40362138 G>A), RS1004591280 (17:40360540 T>C), RS1004977277 (17:40361870 C>T), RS1005732378 (17:40365786 C>T)

Disease associations

OMIM: gene MIM:607425 | disease phenotypes: MIM:156000

GenCC curated gene-disease

Mondo (1): Meniere disease (MONDO:0007972)

Orphanet (1): NON RARE IN EUROPE: Menière disease (Orphanet:45360)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90002401_546	Platelet distribution width	2.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007984	platelet component distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008575	Meniere Disease	C09.218.568.217.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other ic — Connexins and Pannexins

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	4
propionaldehyde	increases expression	1
benzo(e)pyrene	decreases methylation	1
entinostat	increases expression	1
nutlin 3	affects cotreatment, increases expression	1
abrine	decreases expression	1
bisphenol S	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Amiodarone	increases expression	1
Camptothecin	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Methapyrilene	decreases methylation, increases expression	1
Nickel	increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Antirheumatic Agents	decreases expression	1

Clinical trials (associated diseases)

31 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01574313	PHASE4	COMPLETED	Effect of Stellate Ganglion Block on Meniere’s Disease
NCT02529475	PHASE4	TERMINATED	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)
NCT04815187	PHASE4	ACTIVE_NOT_RECRUITING	Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere’s Disease
NCT03664674	PHASE3	COMPLETED	Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere’s Disease
NCT04677972	PHASE3	COMPLETED	SPI-1005 for the Treatment of Meniere’s Disease
NCT05851508	PHASE3	RECRUITING	The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere’s Disease
NCT05420350	PHASE2	UNKNOWN	Lamotrigine and Bupropion for Meniere’s Disease
NCT06544434	PHASE2	RECRUITING	Laser Acupuncture for Meniere Disease
NCT04674735	PHASE1	WITHDRAWN	Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere’s Disease
NCT04218123	PHASE2/PHASE3	COMPLETED	Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere’s Disease Outcomes
NCT04766853	PHASE1/PHASE2	COMPLETED	Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
NCT04794842	EARLY_PHASE1	UNKNOWN	Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection
NCT00599560	Not specified	COMPLETED	Vasopressin and V2 Receptor in Meniere’s Disease
NCT02371798	Not specified	WITHDRAWN	Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
NCT03520322	Not specified	TERMINATED	A Study of a Mastoid Device in Subjects With Ménière’s Disease
NCT03795675	Not specified	ACTIVE_NOT_RECRUITING	CI Following VS Removal or Labyrinthectomy
NCT04370366	Not specified	RECRUITING	Imaging of Endolymphatic Hydrops at 7T MRI
NCT04569175	Not specified	COMPLETED	Non Enhanced Labyrinth Imaging for the Detection of Endolymphatic Hydrops in Meniere’s Disease NELI Study
NCT04686695	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Meniere Disease
NCT04835688	Not specified	UNKNOWN	Ventilation Tube Insertion for Unilateral Menière’s Disease
NCT04902963	Not specified	COMPLETED	What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube?
NCT04935970	Not specified	UNKNOWN	Metabolic Disorders and Vertigo
NCT05322538	Not specified	NOT_YET_RECRUITING	Menier’s Disease - Bone Density Study
NCT05328895	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
NCT05424302	Not specified	RECRUITING	Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy
NCT05582148	Not specified	UNKNOWN	Meniere Disease and Hearing Aids
NCT05844657	Not specified	COMPLETED	Comprehensive Evaluation in Patients With Meniere’s Disease
NCT05960786	Not specified	COMPLETED	Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
NCT06278129	Not specified	UNKNOWN	Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière’s Disease
NCT06544590	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
NCT07272473	Not specified	RECRUITING	Effects of Cervical Mobilization on Dizziness, Balance, and Joint Position Sense in Patients With Meniere’s Disease